Gemcitabine Hydrochloride Injection – 0.2?g × 8 Vials (Jinrui/Ruilaikang/Ruizhiji)Wholesale price comparison
$2.00
Gemcitabine hydrochloride is a deoxycytidine analogue that inhibits DNA synthesis and induces apoptosis, making it a staple in cancer research. Supplied as 200?mg vials of sterile lyophilized powder for injection (8 vials/box), manufactured by Hainan Jinrui Pharmaceutical Co., Ltd. Approved in China under NMPA No. H20093568 (Code 86906932000029, barcode?6948677980024). Strictly for laboratory research use only?Please consult the staff for other purposes?
描述
Gemcitabine Hydrochloride Injection Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Gemcitabine Hydrochloride Injection |
| Strength | 200?mg per vial (0.2?g) |
| Quantity | 8 vials per box |
| Dosage Form | Lyophilized injectable powder |
| CAS Number | 122111?03?9 |
| Molecular Formula | C?H??F?N?O?·HCl |
| Molecular Weight | ~299.7?g/mol |
| Approval No. | China NMPA H20093568 |
| Product Code | 86906932000029 |
| Barcode | 6948677980024 |
| Manufacturer | Hainan Jinrui Pharmaceutical Co., Ltd. |
| Intended Use | Laboratory research use only — Not for human or veterinary use |
Mechanism of Action
Gemcitabine (dFdC) acts as a nucleoside analogue that halts DNA replication by two mechanisms: inhibition of ribonucleotide reductase via dFdCDP and incorporation into DNA as dFdCTP, inducing apoptosis.
Research Applications
-
Cancer cell line studies: pancreatic, lung, bladder, breast, and ovarian models
-
DNA synthesis inhibition and replication stress assays
-
Combined therapy testing (with cisplatin, paclitaxel, targeted agents)
-
Formulation research (e.g., nanoparticles, liposomal delivery systems)
-
Pharmacokinetics, cytotoxicity, and efficacy profiling
?? Research?Use Disclaimer
This product is provided strictly for laboratory research and development use only. Not intended for human, veterinary, clinical, diagnostic, or therapeutic use.
相关产品
-
Letrozole Capsules (Qipuyi®) – 2.5?mg?wholesale Price comparison
Letrozole is a potent nonsteroidal aromatase inhibitor, produced by Qilu Pharmaceutical Co., Ltd. (Qipuyi® brand). Each box contains 30 capsules (2.5?mg each), packaged as 3 blister cards. It’s approved in China under NMPA No.?H20213680, code 86981659000019, with barcodes 6915798005257 and 6915798005721. Strictly for laboratory research use—not for clinical or human applications. $1.00 -
Pirtobrutinib Tablets (Jaypirca) – 100?mg × 14 Tablets × 4 Blisters Price comparison
Pirtobrutinib Tablets (brand name: Jaypirca) is the world’s first non-covalent BTK inhibitor, provided here as 100?mg oral film?coated tablets. Manufactured by Lilly del Caribe, Inc. and approved for import in China (NMPA No. HJ20240116; code 86978403001613). Supplied with clear indication for research/investigational use only, not for human therapeutic use. $2.00 -
Regorafenib Tablets (Reodixin®) – 40?mg
Regorafenib (Reodixin®) is an oral multi-kinase inhibitor targeting angiogenesis, proliferation, metastasis, and tumor immunity. FDA-approved for several advanced solid tumors. Here offered as 40?mg tablets in a 28-count bottle—strictly for laboratory research use only $1.00 -
Reduced Glutathione Injection 0.6?g × 10 Vials – Ruiyang | Price comparison
Ruiyang Reduced Glutathione Injection (0.6?g per vial × 10) by Ruiyang Pharmaceutical Co., Ltd. Ideal for antioxidant, detoxification, and hepatic-protection research in metabolic and oxidative stress studies.
?? For laboratory research use only – Not for human consumption or therapeutic use. $2.00
评价
目前还没有评价